COFEPRIS Reclassifies Tramadol as Controlled Medication

Mexico's COFEPRIS announced that tramadol will be reclassified as a controlled medication starting July 14, 2026, under Article 245 of the General Health Law. Pharmacies must dispense the drug only with a simple medical prescription and record every transaction in official control books. 

Mexico's Federal Commission for the Protection Against Sanitary Risks (COFEPRIS) says that tramadol will become a controlled medication starting July 14, 2026. The reclassification places tramadol under Fraction III of Article 245 of the General Health Law.

The new rule requires pharmacies to dispense the drug only when presented with a medical prescription. Pharmacies must also log every transaction in official control books.

The measure does not remove tramadol from the market, and it does not require a special prescription. A prescription issued by a physician with a valid professional license remains sufficient for dispensation.

For an industry accustomed to periodic tightening of controlled-substance rules, the relevant shift is procedural. Pharmacies, distributors, warehouses, manufacturers, and importers must now document the medication's movement with a level of traceability not previously required for tramadol.

Tramadol is widely used for pain management across outpatient and hospital settings in Mexico. COFEPRIS says the reclassification is a preventive measure against inappropriate use and dependence risk, rather than a restriction on clinical access. For hospitals, clinics, private practices, hospital pharmacies, and pharmacy chains, the change requires a review of how prescription, dispensation, and recordkeeping are coordinated internally.

The regulatory challenge is balancing two objectives: reinforcing sanitary control and avoiding unnecessary barriers for patients who require the medication under medical supervision. 

What the Reclassification Changes, and Its Legal Basis

The reclassification stems from a decree reforming, adding to, and repealing various provisions of the General Health Law, published in the Official Gazette of the Federation on January 15, 2026.

That reform modified Article 245, which governs the classification of psychotropic substances, and incorporated tramadol into Fraction III. Mexico's regulatory framework already separates medications into distinct control categories under the General Health Law, a structure that has shaped how highly specialized and controlled medications reach pharmacy shelves across the country.

Under the new rules, physicians retain the ability to prescribe tramadol through a simple medical prescription, provided they hold a valid professional license. Pharmacies, however, take on specific new duties at the point of sale. Staff must stamp the prescription, record the date and quantity dispensed, and log the transaction immediately in the corresponding control books.

Sanitary managers within pharmacy chains and hospital pharmacies will need to verify that internal procedures reflect the new classification. Distributors, warehouses, manufacturers, and importers must reinforce traceability and documentation across the supply chain.

Patients maintain access to the medication when a medical indication exists. Dispensation will now occur under a documented, controlled framework rather than an unrestricted one. 

Pharmaceutical and Health Sector

The tramadol reclassification fits into a broader pattern of COFEPRIS tightening oversight of medications with potential to create dependence. Pharmaceutical distributors and hospital procurement teams in Mexico have tracked this trend closely, particularly as the agency has also moved to reinforce traceability across the pharmaceutical supply chain amid rising concern over irregular and diverted medicines.

Companies operating multi-state pharmacy networks face a coordination challenge. Control book procedures and staff training must be standardized across locations to avoid inconsistent compliance postures ahead of a sanitary inspection.

For international pharmaceutical companies and distributors evaluating the Mexican market, the episode illustrates how the country's regulatory framework increasingly separates commercial availability from access controls. A medication can remain fully accessible to patients through legitimate clinical channels while carrying documentation and traceability requirements comparable to more heavily restricted substances.

Businesses assessing regulatory risk in Mexico's pharmaceutical sector should treat this as a template. Reclassification announcements under Article 245 are tied to fixed transitory timelines set at the moment of legislative reform, not to subsequent administrative notices. Monitoring the Official Gazette directly offers longer lead time than waiting for COFEPRIS's operational confirmations.

Compliance will depend on how consistently pharmacies, physicians, distributors, and sanitary managers apply the new requirements once the reclassification takes effect on July 14. COFEPRIS says the priority for the health system is sustaining access for patients who require pain management, while introducing clearer rules for prescription, dispensation, and recordkeeping. 

For pharmacies and health institutions, this points toward a narrow compliance window. Establishments that dispense or otherwise participate in the tramadol supply chain have limited time to confirm that sealing procedures, control book formats, and inventory reconciliation processes meet the new standard before enforcement begins.

COFEPRIS has not signaled a phased rollout or grace period beyond the 180-day transitory window already built into the January decree. Establishments that have not adjusted internal procedures by the effective date face immediate exposure during any sanitary review.